19 January 2016 - Richard Pazdur, M.D., Director of the FDA's Office of Hematology and Oncology Products, highlights some of his office’s 2015 approvals and discusses a few of the expedited review programs that are used by the office.

For more details, go to: http://www.fda.gov/Drugs/NewsEvents/ucm482172.htm